GLIOBLASTOMA FOUNDATION INC
EIN: 81-2849764Durham, NCZIP: 27705
H30 - Medical Research501(c)(3)
Mission
THE GLIOBLASTOMA FOUNDATION IS DEDICATED TO FINDING A CURE FOR GLIOBLASTOMA BY FUNDING RESEARCH AND DRUG DEVELOPMENT, SUPPORTING PATIENTS AND FAMILIES, AND RAISING NATIONAL AWARENESS OF THIS DEVASTATING BRAIN CANCER. THROUGH THESE INTEGRATED PROGRAMS, THE FOUNDATION ACCELERATES SCIENTIFIC DISCOVERY, EMPOWERS PATIENTS WITH INFORMATION AND RESOURCES, AND EDUCATES THE PUBLIC ABOUT THE URGENT NEED FOR BETTER TREATMENTS AND IMPROVED OUTCOMES.
Financials
| Year | Revenue | Expenses | Assets |
|---|---|---|---|
| 2024 | $2.1M | $0 | $3.7M |
| 2023 | $1.7M | $0 | $2.5M |
Compensation
2024
2023
Similar Organizations
PROJECT DS INC
$2.9M revenueMorrisville, NC
Same sector (H30)Comparable revenue ($2.9M vs $2.1M)Same state (North Carolina)
NO ONE LEFT ALONE
$1.2M revenueCharlotte, NC
Same sector (H30)Comparable revenue ($1.2M vs $2.1M)Same state (North Carolina)
NORTH CAROLINA PEDIATRIC SOCIETY INC
$1.8M revenueRaleigh, NC
Similar sector (H)Similar revenue ($1.8M vs $2.1M)Same state (North Carolina)
ORTHOCAROLINA RESEARCH INSTITUTE INC
$1.8M revenueCharlotte, NC
Similar sector (H)Similar revenue ($1.8M vs $2.1M)Same state (North Carolina)
FORE BATTEN FOUNDATION
$1.1M revenueChapel Hill, NC
Similar sector (H)Comparable revenue ($1.1M vs $2.1M)Same state (North Carolina)
READDI INC
$1.5M revenueDurham, NC
Similar sector (H)Comparable revenue ($1.5M vs $2.1M)Same state (North Carolina)
Rome Foundation
$2.9M revenueRaleigh, NC
Similar sector (H)Comparable revenue ($2.9M vs $2.1M)Same state (North Carolina)
REGENMED DEVELOPMENT ORGANIZATION
$1.2M revenueWinstonsalem, NC
Similar sector (H)Comparable revenue ($1.2M vs $2.1M)Same state (North Carolina)
SPIROVATION INC
$1.1M revenueChapel Hill, NC
Similar sector (H)Comparable revenue ($1.1M vs $2.1M)Same state (North Carolina)
RENU LIFE EXTENDED
$2.8M revenueGoldsboro, NC
Similar sector (H)Comparable revenue ($2.8M vs $2.1M)Same state (North Carolina)
Data from IRS Form 990 filings (2023-2024).